Literature DB >> 8476504

Delivery of antisense oligonucleotides by poly(L-lysine) conjugation and liposome encapsulation.

J P Clarenc1, G Degols, J P Leonetti, P Milhaud, B Lebleu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8476504

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN： 0266-9536


× No keyword cloud information.
  14 in total

1.  Inhibition of luciferase expression by synthetic hammerhead ribozymes and their cellular uptake.

Authors:  B Bramlage; S Alefelder; P Marschall; F Eckstein
Journal:  Nucleic Acids Res       Date:  1999-08-01       Impact factor: 16.971

2.  The spherulites(TM): a promising carrier for oligonucleotide delivery.

Authors:  N Mignet; A Brun; C Degert; B Delord; D Roux; C Hélène; R Laversanne; J C François
Journal:  Nucleic Acids Res       Date:  2000-08-15       Impact factor: 16.971

Review 3.  Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides.

Authors:  Johannes Winkler
Journal:  Ther Deliv       Date:  2011-07

Review 4.  Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects.

Authors:  R A Stull; F C Szoka
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

Review 5.  Application of antisense DNA method for the study of molecular bases of brain function and behavior.

Authors:  S Ogawa; D W Pfaff
Journal:  Behav Genet       Date:  1996-05       Impact factor: 2.805

Review 6.  Facilitating oligonucleotide delivery: helping antisense deliver on its promise.

Authors:  A M Gewirtz; C A Stein; P M Glazer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

7.  Antisense properties of duplex- and triplex-forming PNAs.

Authors:  H Knudsen; P E Nielsen
Journal:  Nucleic Acids Res       Date:  1996-02-01       Impact factor: 16.971

Review 8.  Antisense oncogene and tumor suppressor gene therapy of cancer.

Authors:  W W Zhang
Journal:  J Mol Med (Berl)       Date:  1996-04       Impact factor: 4.599

9.  Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells.

Authors:  R V Giles; D G Spiller; J Grzybowski; R E Clark; P Nicklin; D M Tidd
Journal:  Nucleic Acids Res       Date:  1998-04-01       Impact factor: 16.971

10.  Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide.

Authors:  J P Bongartz; A M Aubertin; P G Milhaud; B Lebleu
Journal:  Nucleic Acids Res       Date:  1994-11-11       Impact factor: 16.971
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.